Search Results
Nov 25, 2025, 04:44 ET 메나리니 그룹, 제67회 미국혈액학회 연례 학술대회에서 ELZONRIS®(tagraxofusp-erzs) 관련 신규 데이터 발표
한다. 간독성 ELZONRIS 치료는 간 효소 상승과 관련이 있다. 임상시험에서 ALT 상승은 79% (96/122명), AST 상승은 76% (93/122명)에서 보고됐다. Grade 3 ALT 상승은 26% (32/122명), Grade 3 AST 상승은 30% (36/122명), Grade 4 AST 상승은 3% (4/122명)에서 보고됐다. 대부분의 간 효소 상승은 1주기(Cycle 1)에서 발생했으며,
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 16:52 ET Menarini Group gibt neue Daten zu ELZONRIS® (Tagraxofusp-erzs) bekannt, die auf der 67. Jahrestagung und Ausstellung der American Society of Hematology vorgestellt werden
Leberenzyme in Verbindung gebracht. Bei Patienten, die ELZONRIS in klinischen Studien erhielten, traten Erhöhungen der ALT bei 79 % (96/122) und Erhöhungen der AST bei 76 % (93/122) auf. ALT-Erhöhungen des Grades 3 wurden bei 26 % (32/122) der Patienten festgestellt. AST-Erhöhungen des Grades 3 wurden bei
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 16:44 ET Menarini Group annonce de nouvelles données sur ELZONRIS® (tagraxofusp-erzs) qui seront présentées lors de la 67e réunion annuelle de l'American Society of Hematology
observées chez la majorité des patients au cours du cycle 1 et ont disparu après l'interruption de la dose.Surveiller l'alanine aminotransférase (ALT) et l'aspartate aminotransférase (AST) avant chaque perfusion d'ELZONRIS. Interrompre temporairement l'administration d'ELZONRIS si les transaminases
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
increases in alanine aminotransferase (ALT) (2 to 6%) and aspartate aminotransferase (AST) (2 to 3%) were reported in patients receiving Verzenio. Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87
More news about: Eli Lilly and Company
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
AST increased (17; 1.6), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), alkaline phosphatase increased (11; -), ALT increased (11; 1.6), potassium increased (11; 0.8). Grade 4 laboratory abnormalities in >5% of patients included neutrophils decreased (10), platelets
More news about: Eli Lilly and Company
Nov 24, 2025, 10:27 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122)
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 10:20 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122)
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 21, 2025, 08:37 ET Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
medical management.HepatotoxicityLYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
Nov 20, 2025, 11:29 ET As tariffs drive up costs, Cavela AI secures $6.6M to help e-commerce brands pivot production fast
product lines. "We were told there were only two manufacturers who could make our product. Cavela found us three times as many options" Anastasia Alt, Founder of Yana. "Tariffs have put e-commerce in an existential crisis. Cavela makes premium manufacturing accessible to all brands," said Ross Fubini,
More news about: Cavela
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
IMDELLTRA® can cause hepatotoxicity. In the pooled safety population, based on laboratory data, elevated ALT occurred in 39% of patients who received IMDELLTRA®, including 2.5% with Grade 3 or 4 ALT. Elevated AST occurred in 43% of patients, including 3.2% Grade 3 or 4. Elevated bilirubin also occurred
More news about: Amgen
Nov 19, 2025, 07:00 ET First Alt® Marks Three Years of Growth - Redefining Safety, Innovation, and Equity in Alternative Student Transportation
intelligent route optimization, and consistent driver assignments, First Alt ensures every student arrives safely, on time, and ready to learn. About First AltFirst Alt, the alternative transportation service offering of First Student, provides
More news about: First Student
Nov 19, 2025, 06:01 ET VIK IN CHILE IS NAMED NO.1 IN THE LIST OF THE WORLD'S 50 BEST VINEYARDS 2025
Alt Penedés
More news about: 50 Best
Nov 18, 2025, 11:00 ET European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence
More news about: Insmed Incorporated
Nov 17, 2025, 08:05 ET Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
HepatotoxicityREZLIDHIA can cause hepatotoxicity, presenting as increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased blood alkaline phosphatase, and/or elevated bilirubin. Of 153 patients with relapsed or refractory
More news about: Rigel Pharmaceuticals, Inc.
Nov 14, 2025, 12:31 ET Lernen im Auge des Sturms
Sundus nicht verwirklichen konnte. Als Sundus sieben Jahre alt war, wurde ihr Dorf überschwemmt und die Fluten verschlangen ihr Haus und den Hof der Familie. Ihre Familie floh in das Flüchtlingslager Towfiq. Einst
More news about: Education Cannot Wait
Nov 14, 2025, 02:13 ET PR Newswire Powers the AI Era, Embracing the Future of AI Search and Information Discovery
A: Yes, it's a critical component. While LLMs don't "see" images in a human sense, they meticulously analyze the associated text – like alt text, captions, and file names – to understand context. More importantly, multimedia dramatically increases engagement with
More news about: PR Newswire
Nov 11, 2025, 10:00 ET JOEY VALENCE & BRAE ANNOUNCE MONSTER ENERGY OUTBREAK HEADLINE TOUR
CORONA, Calif., Nov. 11, 2025 /PRNewswire/ -- Fast-rising, genre-defying alt/hip hop duo Joey Valence & Brae will be the latest headliners for the Monster Energy Outbreak Tour's 2026 run. The 18-date tour kicks off February
More news about: Monster Energy
Nov 11, 2025, 08:00 ET RuggON Launches VULCAN 10A: AI-Enhanced Rugged Vehicle Mounted Computer Built for Always-On Industrial Mobility
providers, the VULCAN 10A offers multiple industrial I/O interfaces, including CANBus, Gigabit Ethernet, multiple serial ports and USB Type-C with DP Alt Mode, allowing flexible integration with vehicle diagnostics, sensors, and control systems. "The VULCAN 10A embodies RuggON's
More news about: RuggON Corp.
Nov 11, 2025, 08:00 ET RuggON stellt den VULCAN 10A vor: KI-gestützter, robuster Fahrzeugcomputer für permanente industrielle Mobilität
Flottenlösungen bietet der VULCAN 10A mehrere industrielle E/A-Schnittstellen, darunter CANBus, Gigabit-Ethernet, mehrere serielle Anschlüsse und USB Typ C mit DP Alt Mode, was eine flexible Integration mit Fahrzeugdiagnosesystemen, Sensoren und Steuerungssystemen ermöglicht. „Der VULCAN 10A
More news about: RuggON Corp.
Nov 11, 2025, 08:00 ET RuggON lance le VULCAN 10A, un ordinateur embarqué robuste, amélioré par l'IA, conçu pour une mobilité industrielle permanente
flotte, le VULCAN 10A offre de multiples interfaces d'E/S industrielles, notamment CANBus, Gigabit Ethernet, plusieurs ports série et USB Type-C avec DP Alt Mode, ce qui permet une intégration flexible avec les diagnostics, les capteurs et les systèmes de contrôle des véhicules. « Le
More news about: RuggON Corp.
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
mg, with the greatest treatment effect observed for alanine aminotransaminase (ALT) in patients with weight loss of ≤7%. In this subgroup, patients receiving semaglutide 2.4 mg showed a greater mean absolute change in ALT from baseline to Week 72 when compared to those receiving placebo (ETR* 0.75, 95%
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
mg, with the greatest treatment effect observed for alanine aminotransaminase (ALT) in patients with weight loss of ≤7%. In this subgroup, patients receiving semaglutide 2.4 mg showed a greater mean absolute change in ALT from baseline to Week 72 when compared to those receiving placebo (ETR* 0.75, 95%
More news about: NOVO NORDISK INC.
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
baseline TG >80 mg/dl showed favorable tolerability, no serious adverse events, with mild, self-limited injection-site reactions (ISRs) and transient ALT and AST elevations typical of GalNAc-conjugated siRNAs. RN0361 demonstrated dose-responsive suppression of both ApoC3 and TG through Day 180, with a
More news about: Rona Therapeutics
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
baseline TG >80 mg/dl showed favorable tolerability, no serious adverse events, with mild, self-limited injection-site reactions (ISRs) and transient ALT and AST elevations typical of GalNAc-conjugated siRNAs. RN0361 demonstrated dose-responsive suppression of both ApoC3 and TG through Day 180, with a
More news about: Rona Therapeutics
Nov 07, 2025, 19:29 ET U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Elevated liver transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels were reported in patients treated with KYGEVVI. Obtain baseline liver transaminase (ALT, AST) and total bilirubin levels in patients prior to treatment initiation with
More news about: UCB